• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human Pathology >Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy
【24h】

Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy

机译：雄激素受体的表达通常在最初手术切除的乳腺癌转移中得以维持，但在尸检时发现的晚期转移中却常常丢失

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Androgen receptor (AR) is expressed in approximately 70% of primary breast carcinomas (PBCs) and is a promising therapeutic target for metastatic breast carcinoma (MBC). Here, we examine AR expression in a population of initial surgically resected metastases and a separate cohort of end-stage metastases harvested at autopsy compared with their matched PBCs. Tissue microarrays of matched PBC and MBC were labeled by immunohistochemistry for AR, estrogen receptor (ER), progesterone receptor (PR), and Her2 and classified into the following previously described categories: luminal (ER/PR+/Her2-), triple negative (ER/PR/Her2-), Her2 (ER/PR-/Her2+), and luminal loss (ER/PR loss from primary to metastasis). In the cohort of surgically resected metastases (n = 16), AR was expressed in 12 of 16 PBC and maintained in 11 of 12 corresponding MBCs. Of these, 36% showed stronger AR labeling in the metastases and none showed a decrease. In the cohort of metastases harvested at autopsy (n = 16), AR was expressed in 11 of 16 primary carcinomas and maintained in only 5 of 11 corresponding metastases. Of these, none showed increased AR and 80% showed decreased AR labeling. AR expression is overwhelmingly concordant between matched PBC and MBC at initial presentation. These findings validate AR as a therapeutic target in MBC and suggest that AR may need to be reevaluated in metastases even if the primary is negative. However, similar to ER/PR, AR expression is often decreased with a trend toward complete loss in end-stage metastases, suggesting a shift of AR expression between initial and end-stage metastases. This suggests an opportunity for targeted antiandrogen therapy at an earlier stage of disease progression.
机译：雄激素受体（AR）在大约70％的原发性乳腺癌（PBC）中表达，并且是转移性乳腺癌（MBC）的有希望的治疗靶标。在这里，我们检查了在最初手术切除的转移灶和在尸检中收获的末期转移灶的队列中与它们匹配的PBC相比的AR表达。通过免疫组织化学针对AR，雌激素受体（ER），孕激素受体（PR）和Her2的免疫组织化学标记匹配的PBC和MBC的组织微阵列，并将其分类为以下先前描述的类别：管腔（ER / PR + / Her2-），三阴性（ ER / PR / Her2-），Her2（ER / PR- / Her2 +）和管腔丢失（从原发到转移的ER / PR丢失）。在手术切除的转移人群中（n = 16），AR在16个PBC中的12个中表达，并在12个相应的MBC中的11个中得以维持。其中，有36％的人在转移灶中显示出更强的AR标记，而没有人显示出降低。在尸检时收集的转移队列中（n = 16），AR在16种原发癌中的11种中表达，并且在11种相应转移中仅5种得以维持。其中，没有一个显示出增强的AR，有80％的显示出AR标记降低。在最初展示时，匹配的PBC和MBC之间的AR表达极其一致。这些发现证实了AR作为MBC的治疗靶点，并提示即使原发灶为阴性，也需要重新评估AR在转移中的作用。但是，类似于ER / PR，AR表达通常随着终末转移的完全丧失而降低，这表明AR表达在初始和终末转移之间转移。这表明在疾病进展的较早阶段进行靶向抗雄激素治疗的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号